Cover Image
市場調查報告書

細菌性結膜炎:開發平台分析

Bacterial Conjunctivitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 227541
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
細菌性結膜炎:開發平台分析 Bacterial Conjunctivitis - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 42 Pages
簡介

結膜炎是指結膜(覆蓋在眼球白色部分的薄膜)泛紅的發炎狀態。雖然一般皆以「流行性結膜炎」(pink-eye)來泛指流行性(細菌性)結膜炎,但其他諸如過敏反應、受到大氣污染·抽煙·有害煙霧類的化學性刺激也同樣會造成結膜炎。流行性結膜炎常見於兒童,並具有非常強的感染力。

本報告提供全球各國治療細菌性結膜炎所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查結果。

簡介

  • 分析範圍

細菌性結膜炎概要

治療藥的開發

  • 細菌性結膜炎開發中產品:概要

各企業開發中的細菌性結膜炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

細菌性結膜炎治療藥:開發中的產品一覽(各企業)

細菌性結膜炎開發治療藥的企業

  • Cellceutix Corporation
  • 第一三共
  • InSite Vision Incorporated
  • NovaBay Pharmaceuticals, Inc.
  • Ocular Therapeutix, Inc.
  • 千壽製藥
  • Shire Plc

細菌性結膜炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • auriclosene
  • azithromycin
  • azithromycin
  • brilacidin tetrahydrochloride
  • ISV-405
  • levofloxacin
  • mokishifurokisashin鹽酸鹽 SR
  • SHP-640
  • 鹽酸萬古霉素(Vancomycin)

細菌性結膜炎治療藥:最新的藥物簡介

細菌性結膜炎治療藥:暫停開發的產品

細菌性結膜炎相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8514IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2016, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape.

Bacterial conjunctivitis is an inflammation of the conjunctiva caused by pathogenic bacteria. Bacterial conjunctivitis is usually caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus sp, or, less commonly, Chlamydia trachomatis. Symptoms include redness in the white of the eye or inner eyelid, itchy eyes, blurred vision, increased sensitivity to light and burning eyes. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 2 and 1 respectively for Bacterial Conjunctivitis.

Bacterial Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacterial Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacterial Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacterial Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacterial Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bacterial Conjunctivitis Overview
  • Therapeutics Development
    • Pipeline Products for Bacterial Conjunctivitis - Overview
  • Bacterial Conjunctivitis - Therapeutics under Development by Companies
  • Bacterial Conjunctivitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Bacterial Conjunctivitis - Products under Development by Companies
  • Bacterial Conjunctivitis - Companies Involved in Therapeutics Development
    • InSite Vision Incorporated
    • NovaBay Pharmaceuticals, Inc.
    • Shire Plc
  • Bacterial Conjunctivitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • auriclosene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • azithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISV-405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHP-640 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vancomycin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bacterial Conjunctivitis - Dormant Projects
  • Bacterial Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 17, 2015: Manhattan U.S. Attorney Settles Civil Fraud Claims Against Inspire Pharmaceuticals For Its Misleading Marketing Designed To Cause Prescriptions Of Azasite For Non-Fda Approved Uses
      • Mar 17, 2015: InSite Vision Announces Settlement of Patent Infringement Lawsuit Against Mylan Pharmaceutical
      • Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US
      • Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops
      • Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops
      • Jun 17, 2013: InSite Vision Announces Joint Patent Infringement Lawsuit With Merck Against Mylan Pharma
      • Mar 26, 2013: InSite Vision Wins Appeal Of Patent Interference Litigation Against University Of California, San Francisco
      • Jan 05, 2012: University Of California, San Francisco Files Appeal Of USPTO Judgment In Favor Of InSite Vision
      • Nov 28, 2011: InSite Vision Wins Patent Interference Litigation Against University Of California, San Francisco
      • Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bacterial Conjunctivitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Bacterial Conjunctivitis - Pipeline by InSite Vision Incorporated, H2 2016
  • Bacterial Conjunctivitis - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2016
  • Bacterial Conjunctivitis - Pipeline by Shire Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Bacterial Conjunctivitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Bacterial Conjunctivitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top